Chugai Pharmaceutical company profile

4519 · TSE · JPY

Compare Chugai Pharmaceutical
¥7,263.00Change from previous close: −1.05%Absolute change: −¥77.00

Close · November 18, 2026

Company profile

Chugai Pharmaceutical has 5,104 employees and is headquartered in Chuo, Japan.

Chugai Pharmaceutical sells its medicines to customers in Japan and in markets across the world, and it researches, develops, manufactures, imports and exports pharmaceuticals in both. Its product range includes oncology products such as Avastin, Herceptin, Tecentriq, Alecensa, Polivy and Lunsumio, along with Hemlibra, Evrysdi, Mircera, Actemra, Enspryng, PiaSky, Vabysmo and Tamiflu. Among its partnerships, the company is deploying an agentic AI platform with Phylo, Inc. to support biomedical research in drug discovery.

In the fiscal year ended December 2025, revenue reached 1,257.9 billion yen, up 7.5% from the previous year, and net income came to 434.0 billion yen. The company employs 5,104 people. It was founded in 1925 and is headquartered in Chuo, Japan. Formerly known as Chugai Shinyaku Shokai, it took its present name in January 1943, and it is a subsidiary of Roche Holding AG.

Company facts

Industry
Drug Manufacturers - General
Country
Japan
Headquarters
Nihonbashi Mitsui Tower, 103-8324, Chuo
Employees
5,104
Chief executive
Osamu Okuda
Founded
1925
Fiscal year
January - December
Listing
4519 · TSE
Indices
Nikkei 225
Currency
JPY
ISIN
JP3519400000

Chugai Pharmaceutical and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Chugai Pharmaceutical4519Japan$76.25B5,10448.3%24.1
Otsuka Holdings4578Japan$41.01B37,75818.0%17.0
Daiichi Sankyo4568Japan$32.83B20,17112.6%18.8
Astellas Pharma4503Japan$30.89B14,09923.5%12.8
CSPC Pharmaceutical Group1093Hong Kong SAR China$11.47B18,62627.9%10.8
BayerBAYNGermany$61.54B87,77516.5%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Chugai Pharmaceutical with its competitors